- Home
- KYTX vs MIST Comparison
KYTX vs MIST Comparison
Compare KYTX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- MIST
- Stock Information
- Founded
- KYTX 2018
- MIST 2003
- Country
- KYTX United States
- MIST Canada
- Employees
- KYTX N/A
- MIST N/A
- Industry
- KYTX
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- KYTX
- MIST Health Care
- Exchange
- KYTX NYSE
- MIST Nasdaq
- Market Cap
- KYTX 119.7M
- MIST 132.5M
- IPO Year
- KYTX 2024
- MIST N/A
- Fundamental
- Price
- KYTX $4.33
- MIST $1.58
- Analyst Decision
- KYTX Strong Buy
- MIST Strong Buy
- Analyst Count
- KYTX 5
- MIST 2
- Target Price
- KYTX $19.00
- MIST $7.50
- AVG Volume (30 Days)
- KYTX 599.4K
- MIST 2.8M
- Earning Date
- KYTX 08-11-2025
- MIST 08-07-2025
- Dividend Yield
- KYTX N/A
- MIST N/A
- EPS Growth
- KYTX N/A
- MIST N/A
- EPS
- KYTX N/A
- MIST N/A
- Revenue
- KYTX N/A
- MIST N/A
- Revenue This Year
- KYTX N/A
- MIST N/A
- Revenue Next Year
- KYTX N/A
- MIST N/A
- P/E Ratio
- KYTX N/A
- MIST N/A
- Revenue Growth
- KYTX N/A
- MIST N/A
- 52 Week Low
- KYTX $1.78
- MIST $0.63
- 52 Week High
- KYTX $10.08
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- KYTX 63.84
- MIST 45.40
- Support Level
- KYTX $3.80
- MIST $1.48
- Resistance Level
- KYTX $4.39
- MIST $1.64
- Average True Range (ATR)
- KYTX 0.39
- MIST 0.17
- MACD
- KYTX 0.05
- MIST -0.04
- Stochastic Oscillator
- KYTX 93.78
- MIST 18.33
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).